Pulmonx wins FDA nod to launch pivotal trials for emphysema treatment
The FDA grants Pulmonx Investigational Device Exemption to begin pivotal clinical trials of the Zephyr Endobronchial Valve in treating patients with emphysema.
Lung treatment company Pulmonx won FDA approval to begin pivotal clinical trials of its Zephyr Endobronchial Valve in treating patients with emphysema.
The minimally invasive Zephyr device is a one-way bronchial valve designed to reduce volume in diseased areas of the lungs, allowing healthier areas to work better. It's implanted bronchoscopically and can be removed later if necessary, according to a press release.